Advertising
Showing 1 to 15 of 268 entries
DON'T BUY
Tends to avoid companies with a ton of debt. Management missteps, and investors are paying for those. In the depths of a tough turnaround. He'd rather own a VTRS, where the debt is manageable, balance sheet's in better shape, with a better growth trajectory.
biotechnology / pharmaceutical
DON'T BUY
Involved in the opiate crisis. Balance sheet is weak. Overall topline growth is low. Stay away. A lot of problems still to overcome.
biotechnology / pharmaceutical
DON'T BUY

Doesn't offer growth. The stock is weak and will stay weak.

biotechnology / pharmaceutical
BUY
It's time to get back in. They all went crazy and then slid on sympathy when valiant went bust. There is tremendous value here. His model price is $21.26 or 63% upside. They presented earnings and the balance sheet looks great.
biotechnology / pharmaceutical
HOLD
Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.
biotechnology / pharmaceutical
DON'T BUY
They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.
biotechnology / pharmaceutical
DON'T BUY
He sold it at a 50% loss due to price declines in generic drugs. That deflation has decreased lately, which is sort of good news. One of their big drugs came off patent, too.
biotechnology / pharmaceutical
DON'T BUY
A generic drug company that has had troubled times as pricing is becoming very competitive. Buyers are consolidating and squeezing margins. They have a MS drug that was a market leader, but now there are others competing. He would rather own brand name drug companies that can become leaders in their field.
biotechnology / pharmaceutical
DON'T BUY
It has done very well. But they made a huge acquisitions three years ago, taking on a lot of debt. They went through several CEOs. The generic drug space is tough and competitive. Generic drug pricing is limited as we head towards a U.S. election; generics are a target of politicians. Also, there are many lawsuits in the generic drug industry. Generics should do better after the election.
biotechnology / pharmaceutical
DON'T BUY
He is more content owning the major pharma versus generic producers. The competition in the space too intense. They have been involved in the manufacturing of opiod based drugs, which could come under regulatory pressure.
biotechnology / pharmaceutical
COMMENT
There is hope for it. Good news is the generic price declines have subsided, but "less declines" is not where he wants to be right now. Challenged in the next 12-18 months. Could go to low 20s, but structural headwinds for the business.
biotechnology / pharmaceutical
BUY
He'd buy it here. It won't go much lower than current levels based on the chart.
biotechnology / pharmaceutical
DON'T BUY
They do generic drugs, the largest player in the world. They're smart and great at what they do. But they made a big acqusition that pressured their margins and hurt the company. But management has since changed and the company is recovering. They're still reducing their debt. TEVA should continue to grow. But this turnaround will take time.
biotechnology / pharmaceutical
BUY
TEVA vs. GSK Teva is in turnaround with a lot of debt to pay off. They need a boast from their future products moving forward. GSK is higher quality with higher credit rating, and lack Teva's debt woes. GSK is the better bet.
biotechnology / pharmaceutical
SELL
A great company. Generics are fantastic. There are internal issues. A lot of people are getting lured here by single digit earnings growth. The fundamental picture is not strong here. He would take the loss. He would look at an ETF if you want to stay invested in Pharma. (Analysts’ price target is $23.00)
biotechnology / pharmaceutical
Showing 1 to 15 of 268 entries

Teva Pharmaceutical(TEVA-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 2

Stockchase rating for Teva Pharmaceutical is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Teva Pharmaceutical(TEVA-N) Frequently Asked Questions

What is Teva Pharmaceutical stock symbol?

Teva Pharmaceutical is a American stock, trading under the symbol TEVA-N on the New York Stock Exchange (TEVA). It is usually referred to as NYSE:TEVA or TEVA-N

Is Teva Pharmaceutical a buy or a sell?

In the last year, 2 stock analysts published opinions about TEVA-N. 0 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Teva Pharmaceutical.

Is Teva Pharmaceutical a good investment or a top pick?

Teva Pharmaceutical was recommended as a Top Pick by on . Read the latest stock experts ratings for Teva Pharmaceutical.

Why is Teva Pharmaceutical stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Teva Pharmaceutical worth watching?

2 stock analysts on Stockchase covered Teva Pharmaceutical In the last year. It is a trending stock that is worth watching.

What is Teva Pharmaceutical stock price?

On 2021-12-01, Teva Pharmaceutical (TEVA-N) stock closed at a price of $8.18.